Tags : P-I trial

M&A

Immuntep, Collaborates with Merck KGaA and Pfizer for Clinical Trial

Shots: The companies jointly enter into P-I trial evaluating the clinical benefits, combining immune stimulator, Immuntep’s eftilagimod alpha (“efti” or “IMP321”), with Merck and Pfizer’s avelumab. Alliances will jointly develop and commercialize avelumab The Institute of Clinical Cancer Research, will sponsor the trial, conducted & involved under ongoing INSIGHT clinical study evaluating P-II dose of […]Read More

Pharma

Moleculin Reports Dosing of Novel Brain Cancer Drug WP1066 in

Shots: The P-I trial is assessing WP1066 in 15 patients with relapsed brain tumor for 6 to 8mos, testing its safety and tolerability in patients at MD Anderson Cancer Centre WP1066 a novel STAT3i (originated from active ingredient in propolis) has shown promising results in animal studies inhibiting tumor growth with improvement in survival Mayo […]Read More